New review charts a roadmap for biologically informed psychiatric diagnosis using biomarkers and AI.
Key Details
- 1Psychiatric diagnosis still relies on symptom checklists, lacking biological grounding.
- 2Emerging frameworks combine molecular/neuroimaging biomarkers, digital phenotyping, and machine learning integration.
- 3Large consortia (e.g., ENIGMA) tie neuroimaging findings to psychiatric conditions like schizophrenia and depression.
- 4Molecular diagnostic tests (e.g., VeriPsych, EDIT-B) have reached limited clinical adoption; most candidate biomarkers lack clinical utility so far.
- 5AI and multimodal models show promise but face challenges with limited psychiatric datasets, lack of explainability, and real-world validation.
- 6Review emphasizes that objective biological measurement should complement—not replace—clinical judgment.
Why It Matters
For radiology and imaging AI professionals, this review highlights the expanding role of neuroimaging, molecular markers, and AI in mental health, a field historically reliant on subjective measures. Robust integration of imaging and digital phenotyping could reshape diagnosis, steering research and technology development towards actionable and explainable clinical tools.
Source
EurekAlert
Related News
•EurekAlert
AI-Powered OCT Enables Rapid 'Optical Biopsy' for Early Endometrial Cancer Detection
A team at Washington University has developed a catheter-based 3D OCT system with AI to quickly and noninvasively detect early endometrial cancers.
•EurekAlert
AI Clinical Reasoning in Diagnostics and Digital Fatigue in Healthcare
Recent JMIR features explore large language models in clinical diagnostics and digital fatigue among healthcare professionals.
•EurekAlert
KAIST, MIT, Microsoft Develop Efficient AI Image Upsampling for Robotics
KAIST, MIT, and Microsoft have created 'Upsample Anything,' a training-free AI method to restore high-resolution visual data from compressed images with up to 16x improved GPU memory efficiency.